Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label tolerability study of AVANZ Phleum pratense immunotherapy
2011-000057-23Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Nov 2011
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of phleum pratense allergen extract in allergic rhinoconjunctivitis (ARC) and allergic asthma, sponsored by ALK-Abelló. Primary endpoint: Frequency of patients with systemic reactions during the AVANZ dose-escalation phase. Started Nov 2011; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2011-000057-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000057-23.